Profitability Metrics

Gross Margin
69.67%
Operating Margin
56.32%
Net Margin
39.65%

Efficiency Metrics

Revenue per Expense Ratio
2.29
R&D as % of Revenue
1.07%

Earnings Quality

EBITDA Margin
60.23%
Income Tax Rate
25.60%
EPS
4.5700000000

Balance Sheet Analysis

Current Ratio
0.49
Cash Ratio
0.33
Working Capital
$-5.73B
Debt to Equity
26,233,000,000.0
Debt to Assets
68.01%
Equity Ratio
-9.18%

Cash Flow Analysis

Operating Cash Flow Ratio
45.30%
Free Cash Flow Ratio
44.34%
CapEx to Revenue
0.96%
Dividends Paid
$6.78B
Stock Buybacks
$1.00B
Total Shareholder Returns
$7.78B
Cash Position Change
-9.04%

Key Takeaways (2023 FY)

  • Revenue declined by 0.89907192575406%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 4.29%
  • Increased R&D investment by 35.80%

Detailed Growth Metrics

Core Performance

Revenue
-0.90%
Net Income
41.05%
EPS
43.26%
Operating Income
35.34%

Operational Efficiency

R&D Expenses
35.80%
SG&A Expenses
-2.61%
Operating Cash Flow
12.49%
Free Cash Flow
12.92%

Balance Sheet Health

Assets
4.37%
Debt
-1.68%
Book Value per Share
9.69%
Inventory
2.97%

Shareholder Returns

Dividends per Share
4.29%
Shares Outstanding
-1.50%

Long Term Trends

3Y Revenue/Share
2.86%
5Y Revenue/Share
10.92%
3Y Dividend/Share
12.69%
5Y Dividend/Share
32.94%